Rituximab in the First Episode of Paediatric Nephrotic Syndrome
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The study will be a randomized, open-label trial in children with the initial episode of SSNS
and whose state of complete remission after received standard prednisolone, to determine
whether rituximab (a single intravenous infusion of 375 mg/m2) would be noninferior to
corticosteroid alone in maintaining complete disease remission during 12-month of follow-up.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Shanghai Children's Hospital Shanghai Children's Medical Center Shanghai Shen Kang Hospital Development Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine